Aphthous stomatitis
ICD-10 K12.0 · ICD-11 DA01.10.1

Recurrent Aphthous Stomatitis When Topical Agents Have Not Controlled Ulcers

Clinical scenario

This protocol addresses patients with recurrent aphthous stomatitis (RAS) who experience multiple ulcer episodes each month, or who present with severe oral pain and difficulty in eating — and whose condition has not been adequately managed with topical therapy alone.

Previous treatment — goals not achieved

First-line management with topical agents was the initial approach. Options in that line included:

The goals — decreasing symptoms, reducing ulcer number and size, and increasing disease-free periods — were not sufficiently met, indicating a need for escalation.

Next-line approach (partial overview)

When topical management is insufficient, oral systemic therapy — involving immunomodulatory and anti-inflammatory agents — becomes the indicated approach for severe, constantly recurring ulcerations.

The complete structured regimen, including agent selection and sequencing, is available via the link below.
Treatment goals

Decrease in symptoms; reduction in ulcer number and size; increase in disease-free periods.

Instant Access to Structured Evidence-Based Regimens

References

  1. Drug therapy is considered for patients who experience multiple episodes of RAS each month and/or present with symptoms of severe pain and difficulty in eating.
  2. It is indicated for severe and constantly recurring ulcerations; topical management is not effective in these cases.
  3. Pakfetrat et al. conducted a double-blind randomized clinical trial to compare colchicine versus prednisolone (immunomodulant agents) in RAS and reported that low dose prednisolone and colchicine were both effective in treating RAS.
  4. de Abreu et al. reported that clofazimine should be considered for the treatment of RAS.
  5. In severe cases of RAS, immunosuppressive and anti-inflammatory drugs have shown varying degrees of success.
  6. Drugs commonly used include corticosteroids, dapsone, colchicine, thalidomide.
  7. The aim of the treatment of RAS is to decrease symptoms; reduce ulcer number and size; increase disease-free periods.
View source ↗